Results 71 to 80 of about 169,466,874 (244)

End-of-life decisions : a cross-national study of treatment preference discussions and surrogate decision-maker appointments [PDF]

, 2013
Background Making treatment decisions in anticipation of possible future incapacity is an important part of patient participation in end-of-life decision-making.
Evans, N.C., Natalie Evans, Bertolissi, S., Viviane Van Casteren, Pasman H. Roeline, Van Casteren, Viviane, Miccinesi, G., Pasman, H.R., Vega Alonso, Tomás, Block, L. van den, T. Vega Alonso, Onwuteaka-Philipsen, B.D., Van den Block, Lieve, Donker, Gé, S. Bertolissi, Bertolissi, Stefano, Pasman, H Roeline, Block, L., Evans, N., Stefano Bertolissi, Pasman, H.R.W., V. Van Casteren, Van den Block Lieve, Bregje Onwuteaka-Philipsen, Luc Deliens, ?, ?, Bertolissi Stefano, O. Zurriaga, Brearley, Sarah, Donker Gé, Gé Donker, Zurriaga, Oscar, Deliens, L., Onwuteaka-Philipsen, B., Viviane, V.C., Tomás Vega Alonso, Onwuteaka-Philipsen Bregje, H.R. Pasman, Donker, G., Oscar Zurriaga, van Casteren, V., Evans Natalie, L. Van den Block, EUROIMPACT, Miccinesi, Guido, Evans, Natalie, EUROIMPACT on behalf of, Lieve Van den Block, Miccinesi Guido, H Roeline Pasman, Deliens Luc, Zurriaga Oscar, B.D. Onwuteaka-Philipsen, N. Evans, L. Deliens, Deliens, Luc, Zurriaga, O., Vega Alonso Tomás, G. Miccinesi, Casteren, V. van, Onwuteaka-Philipsen, Bregje, Guido Miccinesi, Van Casteren Viviane, G.A. Donker, Alonso, T.V., Vega Alonso, T.   +65 more
core   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Multi-centred mixed-methods PEPFAR HIV care & support public health evaluation: study protocol. [PDF]

, 2010
BACKGROUND: A public health response is essential to meet the multidimensional needs of patients and families affected by HIV disease in sub-Saharan Africa.
McCrone Paul, Irene J Higginson, Faith Mwangi-Powell, Scott Moreland, Mwangi-Powell, Faith, Peter Fayers, Fayers, Peter, Downing, Julia, Harding, Richard, Powell, Richard A., Mwangi-Powell Faith, Moreland, Scott, Simms, Victoria, Paul McCrone, Penfold, Suzanne, Higginson, Irene J.; id_orcid, Fayers Peter, Richard Harding, Victoria Simms, Curtis Siân, Julia Downing, Namisango Eve, Powell, Richard A, Penfold Suzanne, Higginson, Irene J, Simms Victoria, Higginson Irene J, Moreland Scott, Siân Curtis, Eve Namisango, Downing Julia, Suzanne Penfold, Richard A Powell, McCrone, Paul, Curtis, Siân, Powell Richard A, Harding Richard, Namisango, Eve   +37 more
core   +2 more sources

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Kansas Health Care Stabilization Fund General Information [2014]

, 2014
"As of July 1, 2014." "The above information is updated based on enactment of 2014 House Bill 2516. Fund or HCSF means the Health Care Stabilization Fund. Fund law means the Health Care Provider Insurance Availability Act (K.S.A.
Kansas. Health Care Stabilization Fund.
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Patients and health care professionals: Partners in health care in Croatia? [PDF]

, 2013
Objectives. To explore quality in hospitals from the patients’ and health care professionals’ perspective in line with Act on the Protection of Patient Rights. Design.
Montgomery Anthony, Brborovic Hana, Mustajbegovic Jadranka, Milosevic Milan   +3 more
core   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease. [PDF]

, 2011
: Chronic obstructive pulmonary disease (COPD) is a leading cause of disability in all its stages, and death in patients with moderate or severe obstruction.
van der Molen, T, Jones PW, Jones, P., van der Molen, T., Price, D, Price, David, Jones, PW, van der Molen, Thys, Jones, Paul W., Price D, van der Molen T, Price, D.   +11 more
core   +2 more sources

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source